<DOC>
	<DOCNO>NCT02149108</DOCNO>
	<brief_summary>The objective Phase III study evaluate efficacy nintedanib patient metastatic colorectal cancer ( mCRC ) failure previous treatment standard chemotherapy biological agent .</brief_summary>
	<brief_title>Nintedanib ( BIBF 1120 ) v Placebo Refractory Metastatic Colorectal Cancer ( LUME-Colon 1 )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Age &gt; = 18 year Signed informed consent Histologically cytologically confirm colorectal adenocarcinoma Metastatic locally advance disease amenable curative surgery and/or radiotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status = 1 At least one measurable lesion accord Response Evaluation Criteria In Solid Tumours ( RECIST ) version 1.1 Progression standard therapy withdraw standard treatment due unacceptable toxicity . Previous standard treatment must include follow : fluoropyrimidine oxaliplatin : Patients treat oxalipatin adjuvant setting progress within 6 month completion adjuvant therapy must treat oxaliplatin metastatic disease irinotecan bevacizumab aflibercept cetuximab panitumumab patient KRas wt Ras wt tumours The remain standard available therapy recommend investigator best supportive care ( note : previous treatment regorafenib TAS 102 allow agent administer study available patient accord local standard ) Life expectancy least 12 week Hepatic function : aspartate aminotransferase ( AST ) / Alanine Amino Tranferase ( ALT ) = 1.5 X Upper Limit Normal ( ULN ) bilirubin = ULN patient without liver metastasis . AST/ALT = 2.5 X ULN bilirubin = ULN patient liver metastasis . Patients Gilbert syndrome bilirubin &lt; 2 X ULN normal AST/ALT eligible Coagulation parameter : International normalise ratio ( INR ) &lt; 2 partial prothrombin Time ( PTT ) = 2xULN Exclusion criterion : Previous treatment nintedanib toxicity attribute previous anticancer therapy resolve Common Terminology Criteria Adverse Events ( CTCAE ) grade =1 History malignancy last 5 year , particular could interfere interpretation result . Serious concomitant disease medical condition affect compliance trial requirement consider relevant evaluation efficacy safety trial drug , Significant cardiovascular disease History severe haemorrhagic thromboembolic event past 12 month Bleeding thrombotic disorder require anticoagulant therapy warfarin , similar agent require therapeutic INR monitoring Gastrointestinal disorder abnormality would interfere absorption study drug Patient brain metastasis symptomatic and/or require therapy . Patients childbearing potential sexually active unwilling use highly effective method contraception Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>